Physician profile
Michael Lysek
NPI 1265968853
$594.51
in general payments reported to CMS, 2019-2025
12 companies · $123 in 2025
The $123 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $183 · 2020: $121 · 2022: $59.31 · 2023: $89.01 · 2024: $18.46 · 2025: $123.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $231.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $230.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $123.26 | 2025 | Austedo Xr |
| Sunovion Pharmaceuticals INC. | $123.04 | 2019 | |
| Genentech USA, INC. | $86.27 | 2020 | |
| Pfizer INC. | $62.23 | 2019-2023 | |
| Janssen Pharmaceuticals, INC | $57.24 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $36.23 | 2022-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.61 | 2023 | Jardiance |
| Gilead Sciences, INC. | $20.20 | 2022 | |
| Actelion Pharmaceuticals US, INC. | $20.03 | 2020 | |
| Otsuka America Pharmaceutical, INC. | $18.46 | 2024 | Rexulti |
| United Therapeutics Corporation | $14.82 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $12.12 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Lysek listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.